It was discovered that CD22 is a B cell marker and takes a role in cell-cell communication. As a myeloid lineage marker, CD33 (Siglec-3) was discovered, and MAG was identified as an oligodendrocyte identification. The development of antibody-based Siglec agonists coincides with the understanding that Siglecs are a crucial node for eosinophil and mast cell control. Antibody Remodeling Services are great tools for customers to study antibody-based Siglec ligands.
Fig.1 An example describing antibody-lectin chimeras (AbLecs). (Stark, et al., 2022)
Cell surface receptors that identify foreign antigens and chemical fingerprints provided by infections, allergens, and inflammatory illnesses trigger immune cells that drive innate and adaptive immune responses. Co-receptors that have the ability to boost or decrease activation in order to stop unintended immune responses further control these receptors. The Siglecs are a family of co-receptors that are expressed on immune cells and share the ability to recognize ligands that contain sialic acid. Siglecs can modify the signaling of immune cells that interact with other self-cells that express their ligands as a result of their recruitment at the site of cell interaction since sialic acids are present on all mammalian cells. The majority of Siglecs decrease cell signaling by binding to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic domains, however certain Siglecs increase cell signaling by interacting with activatory adaptor proteins like DAP12.
These sorts of Siglec-based antibodies are research hot tops:
CD BioGlyco provides the Antibody Glycoengineering service for customers to research different antibody-based Siglecs ligands.
Eosinophilic inflammation and tissue remodeling were decreased by an agonist antibody that was directed against murine Siglec-F. In humans, Siglec-8 agonism stimulates eosinophil apoptosis whereas Siglec-7 and Siglec-8 activity inhibits mast cell growth. Biologics that target glycan-binding proteins, such Siglec-15 blocking antibody and the P-selectin blocking antibody, are among the most promising therapeutics now in development. These drugs circumvent the difficulties of directly targeting glycans while taking use of the straightforward manufacture and advantageous pharmacokinetics of monoclonal antibodies. CD BioGlyco provides advanced Site-Specific Antibody Conjugation Services, due to antibody-based Siglec ligands having potential in disease treatment, the ADCs platform is a valuable research direction.
CD BioGlyco has powerful ADCs research platforms for customers to explore the potential applications of antibody-based Siglec agonists, and we have a great service team to help customers. If you are interested in our services, please feel free to contact us.
Reference:
